Michael Aberman

Michael Aberman is a highly accomplished professional with a diverse background in the fields of biotechnology, healthcare, and medicine.

He holds an MBA in Healthcare from The Wharton School, an MD in Medicine from the University of Toronto, and a BA in Biology from Cornell University.

Michael Aberman is the Founder and CEO of a Stealth Mode Startup in Biotech and has held various key positions in renowned organizations such as Excision BioTherapeutics, Unnatural Products, Rover Diagnostics, Immunai, Columbia Technology Ventures, Quentis Therapeutics, Inc, Regeneron Pharmaceuticals, Credit Suisse, Morgan Stanley, Antigenics, and New York Presbyterian Hospital.

He has demonstrated expertise in business advisory, board membership, senior advisory, executive roles, strategy, investor relations, biotech analysis, business development, and healthcare management.

With a strong educational foundation and extensive professional experience, Michael Aberman has made significant contributions to the biotechnology and pharmaceutical industries.